P38 Alpha Map Kinase complexed with pyrrolotriazine inhibitor 7V

Experimental Data Snapshot

  • Resolution: 2.00 Å
  • R-Value Free: 0.238 
  • R-Value Work: 0.197 
  • R-Value Observed: 0.199 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.2 of the entry. See complete history


Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-Methylphenylamino)-5-Methyl-Npropylpyrrolo[1,2-F][1,2,4] Triazine-6-Carboxamide (Bms-582949), a Clinical P38? Map Kinase Inhibitor for the Treatment of Inflammatory Diseases

Liu, C.Lin, J.Wrobleski, S.T.Lin, S.Hynes, J.Wu, H.Dyckman, A.J.Li, T.Wityak, J.Gillooly, K.M.Pitt, S.Shen, D.R.Zhang, R.F.McIntyre, K.W.Salter-Cid, L.Shuster, D.J.Zhang, H.Marathe, P.H.Doweyko, A.M.Sack, J.S.Kiefer, S.E.Kish, K.F.Newitt, J.A.McKinnon, M.Dodd, J.H.Barrish, J.C.Schieven, G.L.Leftheris, K.

(2010) J Med Chem 53: 6629-6639

  • DOI: https://doi.org/10.1021/jm100540x
  • Primary Citation of Related Structures:  
    3MVL, 3MVM

  • PubMed Abstract: 

    The discovery and characterization of 7k (BMS-582949), a highly selective p38α MAP kinase inhibitor that is currently in phase II clinical trials for the treatment of rheumatoid arthritis, is described. A key to the discovery was the rational substitution of N-cyclopropyl for N-methoxy in 1a, a previously reported clinical candidate p38α inhibitor. Unlike alkyl and other cycloalkyls, the sp(2) character of the cyclopropyl group can confer improved H-bonding characteristics to the directly substituted amide NH. Inhibitor 7k is slightly less active than 1a in the p38α enzymatic assay but displays a superior pharmacokinetic profile and, as such, was more effective in both the acute murine model of inflammation and pseudoestablished rat AA model. The binding mode of 7k with p38α was confirmed by X-ray crystallographic analysis.

  • Organizational Affiliation

    Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, USA. chunjian.liu@bms.com

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Mitogen-activated protein kinase 14
A, B
366Homo sapiensMutation(s): 0 
UniProt & NIH Common Fund Data Resources
Find proteins for Q16539 (Homo sapiens)
Explore Q16539 
Go to UniProtKB:  Q16539
PHAROS:  Q16539
GTEx:  ENSG00000112062 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ16539
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on 39P

Download Ideal Coordinates CCD File 
C [auth A],
D [auth B]
C22 H23 N7 O3
Binding Affinity Annotations 
IDSourceBinding Affinity
39P Binding MOAD:  3MVM IC50: 3.9 (nM) from 1 assay(s)
PDBBind:  3MVM IC50: 3.9 (nM) from 1 assay(s)
BindingDB:  3MVM IC50: 3.9 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 2.00 Å
  • R-Value Free: 0.238 
  • R-Value Work: 0.197 
  • R-Value Observed: 0.199 
  • Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 67.31α = 90
b = 71.34β = 90.47
c = 72.53γ = 90
Software Package:
Software NamePurpose
DENZOdata reduction
SCALEPACKdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

  • Released Date: 2010-10-13 
  • Deposition Author(s): Sack, J.S.

Revision History  (Full details and data files)

  • Version 1.0: 2010-10-13
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2024-02-21
    Changes: Data collection, Database references, Derived calculations